Perinatal EvidenceCompass
Prepopulated workbenchMED-154

ADHD/psychostimulants — nonstimulant

Atomoxetine

Nonstimulant ADHD treatment

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Atomoxetine
Entity type
single-ingredient drug
Active component(s)
Atomoxetine
Formulation / route / interval
Oral; formulation varies
Attachment entry
Atomoxetine
Separate monograph status
No — cross-reference shared molecule monograph
Identity and cross-reference
Not populated in v0.95
Inventory verification confidence
Moderate — molecule-level source; exact product/jurisdiction pending

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

4 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

A-048Provisional public source

Medicaid data associated early stimulant exposure with preeclampsia and continuation after 20 weeks with preterm birth; atomoxetine negative-control exposure was not associated.

Public-source certainty descriptor
low-to-moderate for small association; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
early and late pregnancy
Comparator
exposed versus unexposed and continuation versus discontinuation
Effect or numbers carried forward

Early stimulant-preeclampsia adjusted RR 1.29 (1.11-1.49); continuation after week 20 versus discontinuation-preterm birth adjusted RR 1.30 (1.10-1.55).

Limitations

Residual confounding by ADHD severity, smoking, healthcare use, and dose; outcome estimates for other endpoints imprecise.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-051Provisional public source

A multinational atomoxetine cohort of about 990 first-trimester exposures found no increase in major overall, cardiac, or limb malformations.

Public-source certainty descriptor
moderate for no large overall effect; specific risks remain imprecise; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
first trimester
Comparator
atomoxetine exposed versus unexposed
Effect or numbers carried forward

Approximately 990 first-trimester exposures; no increase identified in overall, cardiac, or limb malformations.

Limitations

Exposure misclassification, live-birth restrictions, and limited power for specific defects and later outcomes.

Sources, citation controls, and verification state

Linked sources

PMID
36652686
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-052Provisional public source

A 2025 atomoxetine milk study found very low transfer and no reported infant adverse effects, but the sample was small.

Public-source certainty descriptor
moderate for measured transfer; low for infant safety; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
lactation
Comparator
no unexposed infant comparator
Effect or numbers carried forward

n=10 taking 40-100 mg/day; mean RID 0.19%; simulated worst-case RID 0.65%.

Limitations

Small, short-term study; simulated worst-case value; inadequate for newborns and neurodevelopment.

Sources, citation controls, and verification state

Linked sources

PMID
41427840
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-067Provisional public source

FDA prescription labeling uses narrative Pregnancy and Lactation Labeling Rule sections rather than the former A/B/C/D/X letter categories.

Public-source certainty descriptor
high for US regulatory framework
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy and lactation
Comparator
not applicable
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Exact labeling and revision date remain product-specific; non-US systems differ.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending